why choose us

First received: August 25, 2023

Clinical Trial: A Study of DB-1303 vs Investigator's Choice Chemotherapy in Metastatic Breast Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Metastatic Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+)

Brief Summary: The goal of this clinical trial is to assess the efficacy of DB-1303 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (IHC 2+/ISH- and IHC 1+?population.

Read more